Mycronic AB (publ) MYCR
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Add in tranches after the post-earnings jump (e.g., 2–3 incremental buys) and monitor: (1) conversion of the record order book into H2 sales/margins, (2) progress in PCB Assembly Solutions toward the >10% EBIT margin target by end-2027, and (3) any signs of order normalization after the unusually strong Q2 level.
Strong order intake and raised full-year guidance in the Q2 report support the continued ADD signal despite elevated expectations after the share price rise.
Sentiment remains strongly positive following the exceptional Q2 report and raised full-year guidance, with continued focus on AI- and datacenter-related demand.
BUY is the call. Positive is the market mood. Medium risk means some things can go wrong.
Latest change
- 15 Jul 2026 — The company released its Q2/H1 report on July 14 with record-high order intake and raised FY2026 net sales guidance to ~SEK 9.25bn (from 8.75bn). The share price reacted strongly positive intraday.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (4) — follow the company freeAbout the company
Mycronic AB (publ) develops and sells production equipment for the electronics industry, with a strong niche position in photomask writers (Pattern Generators) for display and semiconductor applications. The company is profitable with a net cash balance, but has recently faced margin pressure and softer order intake in some divisions.
Bull case
Continued large SLX and Prexision orders together with proven margin expansion strengthen the outlook for Pattern Generators.
Bear case
High expectations after the report reaction could lead to volatility if deliveries or margins fall short of the new levels.
Why this signal
Strong order intake and raised full-year guidance in the Q2 report support the continued ADD signal despite elevated expectations after the share price rise.
Recent news
On 28 August Mycronic received a trade-in order for a Prexision 80 Evo worth USD 21–24 million with delivery in Q2 2027. New long-term targets were presented at the Capital Markets Day on 31 August: SEK 20 billion revenue by 2032–2035 and EBIT margin around 25 %.